Multidisciplinary approach to improve spontaneous ADR reporting in the pediatric outpatient setting: a single-institute experience in Korea by unknown
Baek et al. SpringerPlus  (2016) 5:1435 
DOI 10.1186/s40064-016-3151-z
RESEARCH
Multidisciplinary approach to improve 
spontaneous ADR reporting in the pediatric 
outpatient setting: a single-institute experience 
in Korea
Hyun Jeong Baek1, Yoon Sook Cho1, Kwi Suk Kim1, Jin Lee2, Hye Ryun Kang2,3 and Dong In Suh2,4* 
Abstract 
In order to improve the reporting of adverse drug reactions (ADRs) as part of the routine practice at the pediatric 
outpatient department (OPD), we modified our ADR reporting strategy into one that facilitates the reporting process 
by means of a multi-disciplinary approach. In this study, we retrospectively reviewed ADR records during the period 
from March to September 2014 when we changed our reporting process as a part of institutional quality assurance 
(QA) activity. Yearly differences in the number and composition of ADRs were compared, and the descriptive analy-
ses were done for cases reported from OPD during the QA activity in terms of the suspected drugs, type, causality, 
and severity of ADRs. There were 1211 pediatric ADR reports including 520 cases with underlying hemato-oncologic 
diseases during the period of 2014. Among the 691 non-oncologic cases, 76 were reported from the OPD, which was 
a significant increase (347 %) from the 17 cases reported during the previous year. Further analyses of these 76 cases 
revealed that the caregivers (47.4 %) initiated about half of the reports, the most frequently affected organ was the 
skin (32.9 %), and the most frequent suspected drugs were anticonvulsants (14.5 %). In contrast to the in-ward system, 
moderate cases were more frequent (51.3 %) than mild ones. In conclusion, this study provides a profile of pediatric 
ADRs in the OPD, which were largely under-reported during the usual clinical practice. A multi-disciplinary approach 
would improve spontaneous ADR reporting at the pediatric OPD.
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Background
As children grow and develop, their pharmacody-
namic and pharmacokinetic characteristics continu-
ously change until they reach those of adults for whom 
treatments are often designed (Batchelor and Marriott 
2015). Consequently, it is more frequent to find off-label 
prescriptions in this subset of the population (Kimland 
and Odlind 2012), who also have fewer tools to ensure 
homeostasis and are more prone to suffer adverse drug 
reactions (ADRs). The ADR profile is also different to 
adults in terms of type and frequency, and more careful 
monitoring is required (Blake et al. 2014; Yu et al. 2015). 
In the clinical practice, however, there is a lack of data 
describing pediatric ADRs, not to mention high quality 
evidence regarding their underlying mechanisms.
Pharmacovigilance on subjects attending the outpa-
tient department (OPD) is more challenging than on in-
patients due to the difficulty for collecting and analysing 
ADR data. Under a surveillance system based on spon-
taneous reporting, ADR collection is largely affected by 
the disease type and the resources available to the phy-
sician during the patient visit, i.e. time allowed for each 
patient, available diagnostic tools, access to an electronic 
system for recording and reporting ADRs, and a cultural 
acceptance to discuss the adverse reactions (Vallano et al. 
2005; Black et al. 2015). In Korea, medical expenses are 
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largely shared by the governmental insurance system so 
that patients can easily access tertiary hospitals (Song 
2009), which are located mostly in large cities. In turn, 
such institutions have transformed their practice pattern 
to maximize the number of treated patients by constrain-
ing the required time per subject. As a result, whereas the 
institutional physicians can efficiently treat patients for a 
wide variety of illnesses in this short period, they struggle 
to properly collect and evaluate ADR data associated with 
their prescriptions. On the other hand, there are further 
obstacles to assessing ADRs in OPD patients than in in-
patients, e.g., they do not remain at the hospital for long, 
and it is not possible to perform any further laboratory 
tests or imaging studies (Hazell and Shakir 2006). Finally, 
reporting ADRs in the OPD is less motivating for physi-
cians since it is not their primary duty and requires an 
additional time and effort from which they do not obtain 
immediate feedback. Even for some physicians, reporting 
is deferred for fear of legal issues (Al-arifi et al. 2015).
There have been a number of reports investigating 
ADR profiles in the OPD (Digra et al. 2015; Horen et al. 
2002; Bourgeois et  al. 2009, 2010), but not many are 
available concerning pediatric populations. In 2014, as 
part of a program to try to improve quality and safety, our 
institution ran a campaign to ameliorate ADR reporting 
in the OPD by replacing the existing surveillance system 
with a multi-disciplinary one.
In this report, we aim to (1) share the experience of our 
activities to promote ADR reporting in OPD, (2) compare 
the numbers of ADR cases before and after modifying the 
surveillance system, and (3) describe the current profile 
of ADRs in a Korean tertiary children’s hospital, exclud-
ing anti-neoplastic treatments and vaccinations.
Results
The number of reported ADRs is depicted in Fig. 1. From 
March 2014 to September 2014 the total number of 
reported ADRs, including ward and OPD ADRs was 1211, 
which meant a 21.5 % increase from the 997 reported dur-
ing the same period in 2013. The number of cases reported 
in the pediatric oncology division including both the ward 
and the OPD was 520, which was a 4.1 % decrease from the 
542 reported during the same period in the previous year. 
On the other hand, the number of reported ADRs from 
divisions other than pediatric oncology was 691, which 
meant a 51.9 % increase from the 455 reported during the 
same period in 2013. Our study focused on the 76 cases 
that were reported from the non-oncological OPD, which 
meant a 347 % increase in ADR reports compared to the 
17 cases reported from March to September in 2013. After 
classifying the reported cases according to hospital divi-
sion, we observed that the most cases were reported from 
the division of allergy/pulmonology, followed by neurol-
ogy, nephrology, endocrinology, and cardiology. On the 
other hand, the divisions of gastroenterology and critical 
medicine did not report any case (Fig. 1).
Reporting route
When we analysed the ADR cases according to the 
reporting route, we noticed that various personnel from 
Fig. 1 The number of adverse drug reaction (ADR) cases between the two periods. The central part inside the oval is the magnitude of the com-
parison of ADR numbers according to division of pediatrics except for the oncology one. The black color refers to the hospital divisions other than 
pediatric oncology, in red. Each color of other specific divisions is listed in the figure
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the routine clinical practice had begun to report ADRs. 
Previously it was mainly the pharmacist, who reported 
ADR cases in OPD during their medical chart reviews 
(Table  1). Seventeen (19.7  %) of 76 ADRs in 2014 were 
through the claim calls to nurses at OPD, 14 (18.4  %) 
were claim calls or visits to a pharmacy, and 9 (11.8  %) 
were through questionnaires, which might have been 
missed in the previous system and consisted as many as 
those from the medical personnel (37 and 1 cases from 
doctors and pharmacist, respectively).
ADRs characterization
The main clinical signs and symptoms reported as ADRs 
are listed in Table 2. Skin problems such as rash or urti-
caria were the most frequent manifestation, followed by 
gastrointestinal problems such as nausea, vomiting, diar-
rhoea, or constipation. Generalized symptoms such as 
lethargy came in the third position.
Suspected drugs associated with ADRs are listed 
in Table  3. Drugs with effects on the nervous system, 
including anticonvulsants (anatomical therapeutic chem-
ical [ATC] group N), were the most common suspected 
drugs followed by cardiovascular agents (ATC group 
C) and hormonal remedies, including systemic steroids 
(ATC group H). Respiratory drugs, including antihista-
mines (ATC group R), were the third most common sus-
pected agents followed by antibiotics (ATC group J).
Causality and severity
When we classified the causality considering both ADRs 
and suspected drugs, 55 out of 76 (72.4 %) were catego-
rized as ‘possible’, followed by 18 ‘probable’ cases (23.7 %), 
and two (2.6 %) ‘definite’ cases. Just one (1.3 %) case was 
categorized as ‘doubtful’.
When we classified the ADR cases according to the 
severity, 536 out of 698 (76.8  %) cases were mild, 136 
(19.5  %) were moderate and 26 (3.7  %) were severe 
(Table  4). This was not significantly different from the 
profile of cases in 2013, 374 out of 470 (79.6  %) cases 
were mild, 77 (16.4  %) were moderate and 19 (4.0  %) 
were severe (Chi square test, P = 0.347). When we fur-
ther divided the 2014 cases between ward and OPD 
cases, mild cases ranked the most frequent in the ward 
(502/622, 80.7  %) followed by moderate and severe 
ones. Among the OPD cases, moderate cases were the 
most common (39/76 cases, 51.3  %), followed by mild 
and severe ones. The difference in order and composi-
tion of severity between the ward and the OPD was sta-
tistically significant (Chi square test, P < 0.001). When 
we further review the seriousness in the OPD, 4 and 7 
cases experienced a brief life-threatening event or hos-
pitalization. However, no case became dead or perma-
nently disabled.
Off‑label prescriptions
When we analysed in detail the 76 ADR cases reported 
at the OPD according to the prescription label, 54 cases 
(71  %) were prescribed within label whereas 16 cases 
(21 %) were off-label prescriptions. The remaining 6 cases 
(8 %) were not assessed due to lack of detailed informa-
tion. Among the 16 off-label cases, 4 cases were pre-
scribed out of the age (i.e. zolendronic acid intravenously 
Table 1 Number of adverse drug reaction cases classified by subjects who initiated the report
Initiated by Categories in detail Case, n
2013 March–September 2014 March–September
Medical personnel Doctors during their routine OPD practice 7 37
Pharmacists reviewing doctor’s prescriptions 10
Pharmacists reviewing a withdrawn prescription 1
Patients/caregivers Phone calls to nurses at OPD 15
Phone calls/visits to a pharmacy in hospital 14




Table 2 Symptom manifestations of  pediatric adverse 
drug reactions reported at the outpatient department
Manifestation Cases, n(%)
Rash or urticaria 25 (32.9)
Nausea or vomiting 5 (6.6)
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to a 7 year-old child), 4 cases were out of the dosage or 
route (i.e. somatropin twice as much dose as recom-
mended), and 3 cases were out of the indication (i.e. 
losartan for hematura). Interestingly, the other 5 cases 
were prescribed at a dose lower than the one recom-
mended in the label (Table 5).
Discussion
The major change in the ADR reporting strategy dur-
ing the quality assurance (QA) activity was the replace-
ment of the physician by the pharmacist as the main 
orchestrator of the ADR reporting process. As a result, 
spontaneous ADR reporting was encouraged and there 
was an increase in the number of reported ADRs from 
pediatric patients at the OPD, compared to the previous 
year. The ADR cases reported at the OPD were different 
to those reported in the ward regarding severity and sus-
pected drugs. Moreover, the clinical profile of reported 
ADRs at the OPD was unique from that of other coun-
tries, which reflects the characteristic patterns of clinical 
practice in the Korean children population. This report is 
the first that described ADR profiles of Korean children 
treated at the OPD.
The systems in place for collecting ADR data differ 
between nations, and is inevitably influenced by the pat-
tern of clinical practice and the culture of the country, 
especially where spontaneous reporting is concerned 
(Vallano et  al. 2005; Margraff and Bertram 2014). In 
a Korean tertiary children’s hospital, under a medi-
cal practice pattern that emphasizes efficiency, it is dif-
ficult to gather sufficient information and to properly 
report ADRs. The time pressure routine does not allow 
for screening questions, and ADRs go unnoticed unless 
patients actively voice their complaints. Such a limitation 
has been acknowledged in previously published qualita-
tive research (Vallano et  al. 2005). Moreover, reporting 
ADRs to the database requires additional efforts with no 
immediate reward for physicians, which may explain the 
low ADR reporting frequency recorded during the rou-
tine process in 2013.
As part of our study, we tried to improve the ADR 
reporting in the routine practice by minimizing the 
reporting process. We used a template for physicians, 
which required only the minimum essential pieces of 
data they could gather during the scheduled visit, and 
we asked the nurses to check the list of suspected cases 
and transfer them to the pharmacist. Finally, we let the 
pharmacists review the medical records of the affected 
subjects and fill up the reporting forms for submission to 
the database. Once we established the reporting process, 
claiming calls from the caregivers or patients themselves 
at the drug-distribution site or at the OPD out of the 
practice opening hours were also reviewed by the phar-
macist. As a result, the total number of ADR reports ini-
tiated by the patients or caregivers was almost as high as 
the ones initiated by the physicians.
Nurses in general wards play an important role as 
observers and reporters of ADRs. In the OPD their role 
is different, but it is still important, for they serve as con-
nection between patients, physicians, and pharmacists. 
As a first point of contact with the outpatient they hold 
a unique position to be informed of ADRs by the patients 
themselves. We estimate that about one-fifth of ADRs 
might have been missed if it had not been for the inter-
vention of the nurses.
Table 3 Types of drugs associated with adverse drug reac-
tions
n/a Not associated
Drug categories Anatomical therapeutic 
chemical group
Case, n (%)
Anticonvulsant N 11 (14.5)
Cardiovascular C 10 (13.2)
Steroid/hormonal H 10 (13.2)
Respiratory/antihistamine R 8 (10.5)
Antibiotics J 7 (9.2)
Immunosuppressive L 5 (6.6)
Others n/a 25 (32.9)
Total 76 (100.0)
Table 4 Distribution of  adverse drug reaction severities 
by the year and the clinical setting










Mild 374 (79.6) 536 (76.8) 502 (80.7) 34 (44.7)
Moderate 77 (16.4) 136 (19.5) 97 (15.6) 39 (51.3)
Severe 19 (4.0) 26 (3.7) 23 (3.7) 3 (3.9)
Table 5 Number of cases according to the type of prescrip-
tion
Case, n Case,  %
On label 54 71.1
Off-label 16 21.1
   Indication 3
   Age 4
   Dosage/route 4
   Low dose 5
Data incomplete 6 7.9
Total 76 100.0
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Regarding ADR severity in the OPD, moderate cases 
were more frequent than mild ones, which is different 
from the in-ward reports. In subjects who admitted to 
hospital, the medical personnel may easily notice mild 
ADRs during the observation period. However, mild 
ADRs may not be noticed in the OPD setting unless they 
are mentioned by the patients or caregivers. On the other 
hand, mild ADRs occur mostly briefly so they may not be 
present at the time of the visit. Considering that moder-
ate ADRs require some degree of medical intervention 
(Hartwig et  al. 1992; Davies et  al. 2006), an improved 
reporting of moderate ADRs may be important to recog-
nize potentially harmful ADRs and the drugs that cause 
them.
Regarding anatomical location, the skin and gastroin-
testinal tract were most commonly affected according to 
previous reports carried out in pediatric patients both 
in the ward and in OPD settings (Bourgeois et al. 2009; 
Darnis et  al. 2015; Thiesen et  al. 2013). One interesting 
finding of this report is that lethargy, which is otherwise 
overlooked during the routine practice, was also fre-
quently reported. It implies that in our daily practice we 
need to ask patients actively about their subjective symp-
toms as well as their objective ones. In this study, ATC 
class N (anticonvulsants), R (antihistamines) and J (anti-
biotics) drugs were frequently reported as the suspected 
drugs, in agreement with previous reports (Digra et  al. 
2015; Bourgeois et al. 2009; Jose and Rao 2006; Kaushal 
et  al. 2007). However, vaccines and antipsychotic drugs 
which had been frequently reported in general (Aagaard 
and Hansen 2011; Li et  al. 2014) were missed out in 
this study because OPDs in the psychiatric department 
and routine vaccinations were not included in this QA 
activity.
We excluded cases reported at the division of pediatric 
oncology because chemotherapeutics for cancer are dif-
ferent from other drugs in that their recommended doses 
are determined by maximal tolerable doses and their 
safety margins are narrow (Mathijssen et  al. 2014). This 
could have blunted the clinical profiles of other medica-
tions. On the other hand, pediatric cancer patients are 
frequently admitted to the in-ward or the day-care ward, 
where they have a specialized pharmacist who monitors 
and adjusts the chemotherapeutic regimens. To focus 
on the changes in the non-oncological OPDs, we did not 
apply the QA program to the OPD of pediatric oncology.
This study deals with the activity during a 7-month 
period, which cannot be generalized to the whole year. 
Especially the seasonal variance of prescriptions and 
the external effect of social issues related to drug safety 
could not be reflected on this report. However, the 
QA program was only supported by the institution for 
7 months, and once it finished, we were unable to ensure 
the participation of all the necessary medical personnel. 
Therefore, we compared our results to the data available 
from the previous year during the same period, from 
March to September 2013.
It was not possible to calculate accurately the amount 
of actual ADRs occurred during the OPD practice. 
Although we found a significant increase in the number 
of ADR reports in 2014 compared to the scanty num-
ber in 2013, we assume that many ADRs went unnoticed 
by the authors. In the pediatric OPD, where a continu-
ous monitoring is impossible and the complaints from 
kids are nonspecific or vague, a cultural change to report 
freely ADRs is required. Moreover, we often notice phy-
sicians misjudge ADRs as malpractice and actively dis-
card the reporting, this needs to be overcome in the near 
future in order to develop a successful ADR surveillance 
system (Vallano et al. 2005).
When we further investigated the prescriptions asso-
ciated with ADRs, more than two-thirds were within 
label. Since we lack information on how many prescrip-
tions not associated with ADRs are made off-label, we 
could not confirm or dismiss the well-known hypothesis 
that ADRs in children are greater for drugs prescribed 
off-label than within label (Wallerstedt et al. 2011). Con-
sidering that the incidence of off-label prescriptions is 
lower than that previously reported (Horen et al. 2002), 
and that 31  % of the off-line prescriptions were at the 
“less than recommended doses”, which actually suggests 
that the ADR might also have happened if we prescribed 
them on-label; the relationship between the off-label pre-
scriptions and ADRs is less likely in OPD subjects. How-
ever due to the small sample size, our suggestion cannot 
be generalized to the larger population.
Conclusion
In conclusion, this study suggested a “fine-tune” to 
enhance the ADR monitoring activities. This change in 
our reporting strategy seems very tiny but is exception-
ally effective in medical environments where the physi-
cians are so time-pressed that any activities irrelevant to 
the clinical practice are deferred. Moreover, this study 
provided the profile of the spontaneously reported ADR 
on OPD pediatric subjects in a Korean tertiary hospital. 
More ideas and trials to promote spontaneous report-
ing need to be developed and implemented in the clinical 
practice. The generated evidence will be used to influence 




Seoul National University Children’s Hospital is a tertiary 
general hospital founded 30 years ago, with capacity for 
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311 beds, including 60 intensive care unit beds. Sixteen 
divisions provide outpatient services to 313,000 patients 
yearly. Every year each division of the hospital is encour-
aged to present an innovative proposal to improve the 
quality and safety of the clinical practice, this is known 
as the QA activity. The change in the ADR reporting 
strategy was a part of QA activity proposed by the pedi-
atric outpatient division, and took place from March 
2014 to September 2014. It involved 11 pediatric divi-
sions excluding the pediatric oncology ones, where the 
ADRs are already being intensively monitored in the day-
care ward. The initiative was supported by 27 professors 
belonging to the 11 specialized pediatric divisions that 
handle together about 121,000 patient visits per year.
The ADR monitoring system before and after the QA 
program
The ADR monitoring system of the institute relied largely 
on spontaneous reporting, consisting of medical per-
sonnel that reported suspected ADRs via the electronic 
medical report (EMR) system. Reports were collected 
and comprehensively analysed by the full-time reviewers 
at the regional monitoring centres. After determining the 
suspected medicines, type of adverse reactions, causal 
relationships and outcome, they released the results and 
recommendations to the first responder as a feedback 
report.
The changes made to the surveillance system dur-
ing the QA period are depicted in Fig. 2. Originally, the 
screening and reporting of ADRs in outpatient clinics 
were done in the same manner as in the in-ward system 
i.e. physicians would report while carrying out their usual 
practice, and pharmacists would do it after their retro-
spective review of prescriptions and EMRs, but this sys-
tem did not translate into many ADR reports. Moreover, 
claim calls to the drug-distributing site or the outpatient 
clinic out of the service hours were transferred to the 
OPD nurse, who would eventually contact the physicians 
and let the claimers get informed about their inquiries 
by them. However, since the physicians were not always 
available registering the case, this information was not 
sent to the regional ADR monitoring centre.
In the updated surveillance strategy, nurses and phar-
macists played key roles in gathering and reporting 
ADRs. To minimize any additional burden arising from 
the reporting process, physicians were asked to provide 
the relevant information on the medical chart during 
their usual practice and leave only the list of cases for 
the attending nurse at the end of their turn. The nurse 
then transferred it to the pharmacist on duty who would 
review the medical records of each case and register them 
into the system. The cases reported through claim calls, 
whether received at the OPD or the drug-distribution 
site, were also notified to the pharmacist, who would 
then record, review, and register the suspected ADR 
cases. Moreover, as an additional QA feature, we pre-
pared a questionnaire and made it available at the drug-
distribution desk for patients to assess their experience 
with ADRs and allow them to freely communicate sus-
pected cases to us.
Cases archived in the institutional ADR monitoring 
system were evaluated by specially trained pharmacists 
in order to identify suspected drugs, type and severity 
of ADRs, causality, and recommended course of action. 
The feedback reports were reviewed by the physician 
in charge of the monitoring system and included in the 
patient’s medical records.
Measures
This analysis was a retrospective review of the cases 
reported during this QA activity. The prescriptions and 
feedback reports relevant to each case were categorized 
according to the clinical characteristics of the subjects, 
the reporting source, the suspected drug, the type and 
severity of ADRs, and the association with off-label use. 
Suspected drugs were categorized according to the ATC 
codes (World Health Organization Collaborating Centre 
for Drug Statics Methodology 2015). As a first level clas-
sification, medicines were divided into 14 main groups.
Causal relationships were classified as ‘definite’, ‘prob-
able’, ‘possible’ and ‘doubtful’ according to the Narajo 
algorithm (Naranjo et al. 1981). The severity of ADRs was 
categorized as mild, moderate, and severe based on the 
classification system proposed by Hartwig et  al. (1992) 
and Davies et  al. (2006) and the Common Terminology 
Criteria for Adverse Events (CTCAE) provided by the 
National Cancer Institute version 4.03 (National Cancer 
Institute 2015). Mild ADR referred to cases of Hartwig’s 
level 1–2, which require no medical intervention or sim-
ple discontinuation of suspected drugs. On the other 
hand, moderate ADR referred to cases of Hartwig’s 
level 3–4, which require further management such as an 
administration of antidote or a prolonged hospitaliza-
tion. Finally, severe ADR referred to more severe cases of 
Hartwig’s level 5–7, which result in persistent or signifi-
cant disability that requires intensive medical care, per-
manent harm, or death (Hartwig et al. 1992; Davies et al. 
2006). If the degree of ADR is measurable according to 
the CTCAE, cases of grade 1–2, 3–5, or 6–7 were consid-
ered as the mild, moderate, or severe ADRs.
Off-label prescription was evaluated by verifying pre-
scriptions in terms of the indication, age, dosage, and 
route. The label was defined as the one recorded by 
the Korean ministry of Food and Drug Safety database 
(Korean Ministry of Drug and Food Safety 2015), which 
is similar to the US food and drug administration (US 
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Fig. 2 Change in the reporting strategy. In (a) the previous strategy, physicians reported ADRs that they came across with during or after their 
general practice. Claim calls at the outpatient clinic out of service hours or at the drug-distributing site were transferred to the OPD nurse who 
eventually contacted the physicians and let the claimers get informed about their inquiries. However, during this process no information was sent 
to the regional ADR monitoring centre. In (b) the updated reporting strategy, physician and nurse only had hand over the identifiers to pharmacists, 
and then they report the relevant cases after reviewing the medical records of the suspected cases
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Food and Drug Administration 2015). Under-dose pre-
scription cases were considered separately since they 
were not considered of clinical relevance.
While most comparisons were descriptively analysed, 
the differences in ADR severity between the ward and the 
OPD in 2013 and 2014 were assessed by Chi square tests. 
The review board of Seoul National University Hospi-
tal which supervises conducts at the Children’s Hospital 
approved this protocol (IRB Number was 1504-028-662).
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